SARS-CoV-2 Glycosylation Suggests That Vaccines Should Have Adopted the S1 Subunit as Antigen

Volver a la Vista simple
dc.conicet.fuenteElsevier
dc.conicet.organizacionConsejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Bahía Blanca. Instituto de Química del Sur. Universidad Nacional del Sur. Departamento de Química. Instituto de Química del Sur
dc.conicet.paisOrganizacionArgentina
dc.conicet.produccionid11110847
dc.contributor.authorFernandez, Ariel
dc.date.accessioned2023-09-13T15:38:15Z
dc.date.available2023-09-13T15:38:15Z
dc.date.issued2021-04
dc.date.updated2023-09-13T12:01:03Z
dc.description.abstractExtant SARS-CoV-2 vaccines use the trimeric spike (S) protein as antigen. In the virus, the spike region is extensively glycosylated, modulating immune surveillance. Because they have been defused, many epitopes in the vaccine sidetrack the immune response. Only the receptor binding domain within the S1 subunit is well-exposed to antibody recognition. After proteolytic virus activation, the S1 subunit offers additional epitopes with antibody exposure. Thus, vaccines adopting the S1 subunit as antigen would have been more efficacious than the existing ones.es
dc.description.filFil: Fernandez, Ariel. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Bahía Blanca. Instituto de Química del Sur. Universidad Nacional del Sur. Departamento de Química. Instituto de Química del Sur; Argentina
dc.formatapplication/pdfes
dc.identifier.citationFernandez, Ariel; SARS-CoV-2 Glycosylation Suggests That Vaccines Should Have Adopted the S1 Subunit as Antigen; American Chemical Society; ACS Pharmacology and Translational Science; 4; 2; 4-2021; 1016-1017es
dc.identifier.institucionalCONICET
dc.identifier.issn2575-9108es
dc.identifier.repoCONICET Digital
dc.identifier.urihttp://hdl.handle.net/11336/211392
dc.journal.number2es
dc.journal.pagination1016-1017es
dc.journal.paisEstados Unidoses
dc.journal.titleACS Pharmacology and Translational Sciencees
dc.journal.volume4es
dc.language.isoenges
dc.publisherAmerican Chemical Societyes
dc.relation.alternativeidinfo:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1021/acsptsci.1c00036
dc.rightsinfo:eu-repo/semantics/restrictedAccess*
dc.rights.urihttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/*
dc.subjectCOVID-19 VACCINEes
dc.subjectEPITOPEes
dc.subjectPROTEIN GLYCOSYLATIONes
dc.subjectPROTEOLYSISes
dc.subjectSARS-COV-2es
dc.subjectSTRUCTURAL BIOLOGYes
dc.subjectCOVID-19es
dc.subject.classificationOtras Ciencias Químicases
dc.subject.classificationCiencias Químicases
dc.subject.classificationCIENCIAS NATURALES Y EXACTASes
dc.titleSARS-CoV-2 Glycosylation Suggests That Vaccines Should Have Adopted the S1 Subunit as Antigenes
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:ar-repo/semantics/artículo
dc.typeinfo:eu-repo/semantics/publishedVersion

Archivos

Bloque original

Miniatura
Nombre:
CONICET_Digital_Nro.e3b0ef23-aabc-4d06-b135-1685e8bcf487_B.pdf
Tamaño:
800.48 KB
Formato:
Adobe Portable Document Format
Solicitar

Colecciones

Articulos(INQUISUR)
Volver a la Vista simple